---
document_datetime: 2025-12-02 04:54:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/jcovden.html
document_name: jcovden.html
version: success
processing_time: 0.4050783
conversion_datetime: 2025-12-25 08:03:35.030763
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Jcovden (previously COVID-19 Vaccine Janssen)

[RSS](/en/individual-human-medicine.xml/67439)

##### Withdrawn

This medicine's authorisation has been withdrawn

COVID-19 vaccine (Ad26.COV2-S [recombinant]) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Safety updates](#safety-updates)
- [News on Jcovden (previously COVID-19 Vaccine Janssen)](#news-on)
- [Signal assessment reports](#signal-assessment-reports-1614)
- [External links](#external-links-937)
- [More information on Jcovden (previously COVID-19 Vaccine Janssen)](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 26 July 2024, the European Commission withdrew the marketing authorisation for Jcovden (COVID19 Vaccine Janssen (Ad26.COV2.S)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Janssen-Cilag International N.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Jcovden was granted conditional marketing authorisation in the EU on 11 March 2021 for active immunisation against coronavirus disease 2019 (COVID-19). The conditional marketing authorisation was switched to a standard marketing authorisation, valid for 5 years, on 09 January 2023.

The European Public Assessment Report (EPAR) for Jcovden is updated to indicate that the marketing authorisation is no longer valid.

Jcovden (previously COVID-19 Vaccine Janssen) : EPAR - Medicine overview

Reference Number: EMA/10056/2023

English (EN) (269.31 KB - PDF)

**First published:** 11/03/2021

**Last updated:** 09/08/2024

[View](/en/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-677)

български (BG) (384.63 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/bg/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_bg.pdf)

español (ES) (280.53 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/es/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_es.pdf)

čeština (CS) (366.2 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/cs/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_cs.pdf)

dansk (DA) (272.51 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/da/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_da.pdf)

Deutsch (DE) (298.27 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/de/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_de.pdf)

eesti keel (ET) (253.17 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/et/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_et.pdf)

ελληνικά (EL) (409 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/el/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_el.pdf)

français (FR) (291.83 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/fr/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_fr.pdf)

hrvatski (HR) (324.83 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/hr/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_hr.pdf)

italiano (IT) (267.78 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/it/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (339.93 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/lv/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (339.51 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/lt/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_lt.pdf)

magyar (HU) (342.54 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/hu/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_hu.pdf)

Malti (MT) (361.54 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/mt/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_mt.pdf)

Nederlands (NL) (292.74 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/nl/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_nl.pdf)

polski (PL) (361.86 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/pl/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_pl.pdf)

português (PT) (266.56 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/pt/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_pt.pdf)

română (RO) (331.01 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/ro/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_ro.pdf)

slovenčina (SK) (363.36 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sk/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_sk.pdf)

slovenščina (SL) (331.43 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sl/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_sl.pdf)

Suomi (FI) (264.7 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/fi/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_fi.pdf)

svenska (SV) (263.78 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sv/documents/overview/jcovden-previously-covid-19-vaccine-janssen-epar-medicine-overview_sv.pdf)

COVID-19 Vaccine Janssen : EPAR - Risk-management-plan

English (EN) (2.9 MB - PDF)

**First published:** 11/03/2021

**Last updated:** 09/08/2024

[View](/en/documents/rmp/covid-19-vaccine-janssen-epar-risk-management-plan_en.pdf)

## Product information

Jcovden : EPAR - Product information

English (EN) (1.84 MB - PDF)

**First published:** 11/03/2021

**Last updated:** 09/08/2024

[View](/en/documents/product-information/jcovden-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-251)

български (BG) (1.84 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/bg/documents/product-information/jcovden-epar-product-information_bg.pdf)

español (ES) (2.02 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/es/documents/product-information/jcovden-epar-product-information_es.pdf)

čeština (CS) (1.97 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/cs/documents/product-information/jcovden-epar-product-information_cs.pdf)

dansk (DA) (1.94 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/da/documents/product-information/jcovden-epar-product-information_da.pdf)

Deutsch (DE) (2 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/de/documents/product-information/jcovden-epar-product-information_de.pdf)

eesti keel (ET) (1.89 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/et/documents/product-information/jcovden-epar-product-information_et.pdf)

ελληνικά (EL) (1.83 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/el/documents/product-information/jcovden-epar-product-information_el.pdf)

français (FR) (1.85 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/fr/documents/product-information/jcovden-epar-product-information_fr.pdf)

hrvatski (HR) (1.93 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/hr/documents/product-information/jcovden-epar-product-information_hr.pdf)

íslenska (IS) (1.9 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/is/documents/product-information/jcovden-epar-product-information_is.pdf)

italiano (IT) (1.88 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/it/documents/product-information/jcovden-epar-product-information_it.pdf)

latviešu valoda (LV) (1.89 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/lv/documents/product-information/jcovden-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.84 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/lt/documents/product-information/jcovden-epar-product-information_lt.pdf)

magyar (HU) (1.99 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/hu/documents/product-information/jcovden-epar-product-information_hu.pdf)

Malti (MT) (2.26 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/mt/documents/product-information/jcovden-epar-product-information_mt.pdf)

Nederlands (NL) (1.99 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/nl/documents/product-information/jcovden-epar-product-information_nl.pdf)

norsk (NO) (1.97 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/no/documents/product-information/jcovden-epar-product-information_no.pdf)

polski (PL) (1.96 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/pl/documents/product-information/jcovden-epar-product-information_pl.pdf)

português (PT) (2.12 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/pt/documents/product-information/jcovden-epar-product-information_pt.pdf)

română (RO) (2.12 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/ro/documents/product-information/jcovden-epar-product-information_ro.pdf)

slovenčina (SK) (1.94 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sk/documents/product-information/jcovden-epar-product-information_sk.pdf)

slovenščina (SL) (2.03 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sl/documents/product-information/jcovden-epar-product-information_sl.pdf)

Suomi (FI) (1.95 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/fi/documents/product-information/jcovden-epar-product-information_fi.pdf)

svenska (SV) (1.83 MB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sv/documents/product-information/jcovden-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0076 26/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Jcovden (previously COVID-19 Vaccine Janssen) : EPAR - All authorised presentations

English (EN) (64.79 KB - PDF)

**First published:** 11/03/2021

**Last updated:** 09/08/2024

[View](/en/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-383)

български (BG) (75.33 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/bg/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_bg.pdf)

español (ES) (65.86 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/es/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_es.pdf)

čeština (CS) (74.68 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/cs/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (68.75 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/da/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (69.94 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/de/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (66.64 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/et/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (77.61 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/el/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_el.pdf)

français (FR) (79.26 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/fr/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (77.95 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/hr/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (61.79 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/is/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_is.pdf)

italiano (IT) (66.01 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/it/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (63.16 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/lv/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (70.62 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/lt/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.71 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/hu/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (79.76 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/mt/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (70.24 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/nl/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (63.5 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/no/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_no.pdf)

polski (PL) (80.54 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/pl/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_pl.pdf)

português (PT) (67.9 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/pt/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_pt.pdf)

română (RO) (65.71 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/ro/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (76.86 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sk/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (72.88 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sl/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (61.94 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/fi/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (66.68 KB - PDF)

**First published:**

11/03/2021

**Last updated:**

09/08/2024

[View](/sv/documents/all-authorised-presentations/jcovden-previously-covid-19-vaccine-janssen-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Jcovden (previously COVID-19 Vaccine Janssen) Active substance adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S) International non-proprietary name (INN) or common name COVID-19 vaccine (Ad26.COV2-S [recombinant]) Therapeutic area (MeSH) COVID-19 virus infection Anatomical therapeutic chemical (ATC) code J07BN02

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Jcovden is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/005737 Marketing authorisation holder

Janssen-Cilag International NV

Turnhoutseweg 30

Opinion adopted 11/03/2021 Marketing authorisation issued 11/03/2021 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

COVID-19 Vaccine Janssen : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.8 MB - PDF)

**First published:** 22/04/2021

**Last updated:** 09/08/2024

[View](/en/documents/procedural-steps-after/covid-19-vaccine-janssen-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Jcovden (previously COVID-19 Vaccine Janssen)-H-C-005737-R-0063 : EPAR - Assessment report - Renewal

Reference Number: EMA/CHMP/766600/2022

English (EN) (2.54 MB - PDF)

**First published:** 10/01/2023

**Last updated:** 09/08/2024

[View](/en/documents/variation-report/jcovden-previously-covid-19-vaccine-janssen-h-c-005737-r-0063-epar-assessment-report-renewal_en.pdf)

Jcovden (previously COVID-19 Vaccine Janssen)-H-C-005737-P46-073 : EPAR - Assessment report

Adopted

Reference Number: EMA/738/2023

English (EN) (1.6 MB - PDF)

**First published:** 10/01/2023

**Last updated:** 09/08/2024

[View](/en/documents/variation-report/jcovden-previously-covid-19-vaccine-janssen-h-c-005737-p46-073-epar-assessment-report_en.pdf)

Jcovden (previously COVID-19 Vaccine Janssen)-H-C-PSUSA-00010916-202202 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/830480/2022

English (EN) (713.5 KB - PDF)

**First published:** 15/11/2022

**Last updated:** 09/08/2024

[View](/en/documents/scientific-conclusion/jcovden-previously-covid-19-vaccine-janssen-h-c-psusa-00010916-202202-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

COVID-19 Vaccine Janssen-H-C-5737-II-0033 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/695763/2021

English (EN) (10.69 MB - PDF)

**First published:** 14/01/2022

**Last updated:** 09/08/2024

[View](/en/documents/variation-report/covid-19-vaccine-janssen-h-c-5737-ii-0033-epar-assessment-report-variation_en.pdf)

COVID-19 Vaccine Janssen-H-C-5737-R-0023 : EPAR - Assessment report - Renewal

Adopted

Reference Number: EMA/757560/2021

English (EN) (2.31 MB - PDF)

**First published:** 04/01/2022

**Last updated:** 09/08/2024

[View](/en/documents/variation-report/covid-19-vaccine-janssen-h-c-5737-r-0023-epar-assessment-report-renewal_en.pdf)

## Initial marketing authorisation documents

COVID-19 Vaccine Janssen : EPAR - Public assessment report

Adopted

Reference Number: EMA/158424/2021

English (EN) (13.21 MB - PDF)

**First published:** 19/03/2021

**Last updated:** 09/08/2024

[View](/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for COVID-19 Vaccine Janssen

Adopted

Reference Number: EMA/146391/2021

English (EN) (350.52 KB - PDF)

**First published:** 11/03/2021

**Last updated:** 09/08/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-covid-19-vaccine-janssen_en.pdf)

#### Safety updates

Jcovden : Periodic safety update report assessment 25 February 2024 to 30 September 2024

Adopted

Reference Number: EMA/111356/2025

English (EN) (8 MB - PDF)

**First published:** 01/09/2025

[View](/en/documents/covid-19-vaccine-safety-update/jcovden-periodic-safety-update-report-assessment-25-february-2024-30-september-2024_en.pdf)

Jcovden : Periodic safety update report assessment 25 February 2023 to 24 February 2024

Adopted

English (EN) (18.86 MB - PDF)

**First published:** 05/12/2024

[View](/en/documents/covid-19-vaccine-safety-update/jcovden-periodic-safety-update-report-assessment-25-february-2023-24-february-2024_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 22 April 2021

Adopted

English (EN) (287.95 KB - PDF)

**First published:** 23/04/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-22-april-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 14 April 2021

Adopted

English (EN) (237.41 KB - PDF)

**First published:** 16/04/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-april-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 18 June 2021

Adopted

English (EN) (363.03 KB - PDF)

**First published:** 18/06/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-18-june-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 11 August 2021

Adopted

English (EN) (330.47 KB - PDF)

**First published:** 11/08/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-august-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 11 November 2021

Adopted

English (EN) (306.57 KB - PDF)

**First published:** 11/11/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-november-2021_en.pdf)

Jcovden (previously COVID-19 Vaccine Janssen): Periodic safety update report assessment 25 August 2022 to 24 February 2023

Adopted

English (EN) (4.94 MB - PDF)

**First published:** 08/02/2024

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/jcovden-previously-covid-19-vaccine-janssen-periodic-safety-update-report-assessment-25-august-2022-24-february-2023_en.pdf)

COVID-19 vaccines - Safety update: 14 July 2022

Adopted

Reference Number: Rev. 1

English (EN) (263.34 KB - PDF)

**First published:** 14/07/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-14-july-2022_en.pdf)

COVID-19 vaccines - Safety update: 8 September 2022

Adopted

English (EN) (257.73 KB - PDF)

**First published:** 08/09/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-september-2022_en.pdf)

COVID-19 vaccines - Safety update: 17 March 2022

Adopted

English (EN) (237.65 KB - PDF)

**First published:** 17/03/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-march-2022_en.pdf)

COVID-19 vaccines - Safety update: 6 October 2022

Adopted

English (EN) (237.46 KB - PDF)

**First published:** 06/10/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-6-october-2022_en.pdf)

COVID-19 vaccines - Safety update: 8 December 2022

Adopted

English (EN) (239.73 KB - PDF)

**First published:** 08/12/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-december-2022_en.pdf)

COVID-19 vaccines - Safety update: 10 November 2022

Adopted

English (EN) (254.94 KB - PDF)

**First published:** 10/11/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-10-november-2022_en.pdf)

COVID-19 vaccines - Safety update: 12 May 2022

Adopted

English (EN) (214.22 KB - PDF)

**First published:** 12/05/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-12-may-2022_en.pdf)

Jcovden (previously COVID-19 Vaccine Janssen): Periodic safety update report assessment 25 February 2022 to 24 August 2022

Adopted

English (EN) (8.23 MB - PDF)

**First published:** 10/10/2023

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/jcovden-previously-covid-19-vaccine-janssen-periodic-safety-update-report-assessment-25-february-2022-24-august-2022_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 9 December 2021

Adopted

English (EN) (339.94 KB - PDF)

**First published:** 09/12/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-9-december-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 6 October 2021

Adopted

English (EN) (488.36 KB - PDF)

**First published:** 06/10/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-6-october-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 8 September 2021

Adopted

English (EN) (371.09 KB - PDF)

**First published:** 08/09/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-8-september-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 14 July 2021

Adopted

English (EN) (415.56 KB - PDF)

**First published:** 14/07/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-july-2021_en.pdf)

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 11 May 2021

Adopted

English (EN) (253.98 KB - PDF)

**First published:** 12/05/2021

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-may-2021_en.pdf)

COVID-19 vaccines - Safety update: 13 April 2022

Adopted

English (EN) (228.5 KB - PDF)

**First published:** 13/04/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-13-april-2022_en.pdf)

COVID-19 vaccines - Safety update: 17 February 2022

Adopted

English (EN) (226.15 KB - PDF)

**First published:** 17/02/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-february-2022_en.pdf)

COVID-19 vaccines - Safety update: 17 June 2022

Adopted

English (EN) (249.16 KB - PDF)

**First published:** 17/06/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-june-2022_en.pdf)

COVID-19 vaccines - Safety update: 20 January 2022

Adopted

English (EN) (251.15 KB - PDF)

**First published:** 20/01/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-20-january-2022_en.pdf)

#### News on Jcovden (previously COVID-19 Vaccine Janssen)

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 March 2022](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-march-2022) 11/03/2022

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 13 January 2022](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-january-2022) 14/01/2022

[Increase in manufacturing capacity for COVID-19 vaccines from Janssen, Moderna and BioNTech/Pfizer](/en/news/increase-manufacturing-capacity-covid-19-vaccines-janssen-moderna-biontech-pfizer) 16/12/2021

[COVID-19 Vaccine Janssen: EMA recommendation on booster dose](/en/news/covid-19-vaccine-janssen-ema-recommendation-booster-dose) 15/12/2021

[EMA evaluating data on booster dose of COVID-19 Vaccine Janssen](/en/news/ema-evaluating-data-booster-dose-covid-19-vaccine-janssen) 22/11/2021

[Additional manufacturing site for COVID-19 Vaccine Janssen](/en/news/additional-manufacturing-site-covid-19-vaccine-janssen-0) 07/10/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-september-2021) 01/10/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August - 2 September 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-30-august-2-september-2021) 03/09/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5 August 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-august-2021) 06/08/2021

[COVID-19 Vaccine Janssen: Guillain-Barré syndrome listed as a very rare side effect](/en/news/covid-19-vaccine-janssen-guillain-barre-syndrome-listed-very-rare-side-effect) 22/07/2021

[EMA advises against use of COVID-19 Vaccine Janssen in people with history of capillary leak syndrome](/en/news/ema-advises-against-use-covid-19-vaccine-janssen-people-history-capillary-leak-syndrome) 09/07/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021) 09/07/2021

[Increased manufacturing capacity for COVID-19 Vaccine Janssen](/en/news/increased-manufacturing-capacity-covid-19-vaccine-janssen) 02/07/2021

[Additional manufacturing site for COVID-19 Vaccine Janssen](/en/news/additional-manufacturing-site-covid-19-vaccine-janssen) 25/06/2021

[COVID-19 Vaccine Janssen: authorities in EU take steps to safeguard vaccine quality](/en/news/covid-19-vaccine-janssen-authorities-eu-take-steps-safeguard-vaccine-quality) 11/06/2021

[COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis](/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis) 11/06/2021

[EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome](/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia-syndrome) 07/06/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021) 07/05/2021

[COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets](/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets) 20/04/2021

[COVID-19 Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues](/en/news/covid-19-vaccine-janssen-assessment-very-rare-cases-unusual-blood-clots-low-platelets-continues) 14/04/2021

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021) 09/04/2021

[EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU](/en/news/ema-recommends-covid-19-vaccine-janssen-authorisation-eu) 11/03/2021

[EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen](/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-janssen) 16/02/2021

[EMA starts rolling review of Janssen's COVID-19 vaccine Ad26.COV2.S](/en/news/ema-starts-rolling-review-janssens-covid-19-vaccine-ad26cov2s) 01/12/2020

#### Signal assessment reports

Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) adopted at PRAC meeting 3-6 May 2021

Adopted

Reference Number: EMA/PRAC/227875/2021

English (EN) (10.43 MB - PDF)

**First published:** 21/05/2021

**Last updated:** 09/08/2024

[View](/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-janssen-ad26cov2-s-recombinant-adopted-prac-meeting-3-6-may-2021_en.pdf)

Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) adopted at PRAC meeting 20 April 2021

Adopted

Reference Number: EMA/268126/2021

English (EN) (7.58 MB - PDF)

**First published:** 12/05/2021

**Last updated:** 09/08/2024

[View](/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-janssen-ad26cov2-s-recombinant-adopted-prac-meeting-20-april-2021_en.pdf)

#### External links

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home) (login required)

#### More information on Jcovden (previously COVID-19 Vaccine Janssen)

- [EMEA-002880-PIP01-20-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002880-pip01-20-m01)
- [Jcovden (previously COVID-19 Vaccine Janssen) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen)
- [Jcovden (previously COVID-19 Vaccine Janssen) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen-0)
- [Jcovden (previously COVID-19 Vaccine Janssen) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen-1)
- [id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe - post-authorisation study](https://catalogues.ema.europa.eu/study/49374)
- [An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using Health Insurance Databases in the United States - post-authorisation study](https://catalogues.ema.europa.eu/study/49837)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Healthcare worker cohort - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000094)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS), Vaccine effectiveness against COVID-19 and seasonal influenza among patients presenting to primary care physicians in EU/EEA - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000095)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Vaccine effectiveness and the impact of COVID-19 vaccines through routinely collected exposure and outcome data using health registries - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000101)
- [Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Vaccine effectiveness hospital admission with Severe Acute Respiratory Infection - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000099)

**This page was last updated on** 01/09/2025

## Share this page

[Back to top](#main-content)